IMU (ASX) Ann: Imugene AGM Presentation

Originally posted by Lacan ↑

What I have taken out of the above:

Early-Stage Trials:

Imugene’s novel treatments (VAXINIA, onCARlytics, and azer-cel) are mostly in Phase 1 and Phase 1b trials, meaning efficacy and safety data are still preliminary and limited. This restricts conclusions about long-term effects and survival benefits

Small Sample Sizes and Patient Diversity:

The Phase 1 trials, especially for the azer-cel and onCARlytics therapies, involve small cohorts, which may not capture broader efficacy and safety profiles across diverse populations. This limits generalizability until larger Phase 2 or Phase 3 trials are conducted

Limited Comparative Analysis:

While complete responses have been reported in some cases, a more comprehensive comparative analysis against existing FDA-approved treatments (e.g., traditional CAR T-cell therapies for blood cancers) is lacking. This absence of head-to-head trials limits the understanding of Imugene's therapies’ relative efficacy and cost-effectiveness

Focus on Novel Mechanisms:

Imugene’s approach to using oncolytic viruses (VAXINIA) and CD19-targeted onCARlytics therapy to make solid tumors resemble blood cancer cells is innovative. However, these mechanisms are complex and unproven in solid tumors. The transition from preclinical models to human trials for such approaches can often reveal unforeseen biological challenges

Regulatory Hurdles and Uncertain Timelines:

Despite FDA designations for faster review (e.g., Fast Track and Orphan Drug Designations), Imugene's path to market is unclear given their heavy reliance on Phase 1 results. It may take years before obtaining FDA approval if Phase 2 and Phase 3 results are required, impacting short-term valuation

Potential and Valuation

Market Demand for Novel Cancer Therapies:

Imugene’s focus on CAR T-cell and oncolytic virus therapies addresses a high-demand area in oncology. The potential for an allogeneic (off-the-shelf) CAR T-cell treatment could significantly lower costs and increase accessibility compared to autologous (patient-specific) therapies. If successful, azer-cel could attract considerable market interest in diffuse large B-cell lymphoma (DLBCL) and potentially expand into other blood cancers

Differentiated Mechanisms with Broad Applications:

The onCARlytics platform uniquely targets solid tumors by making them appear as CD19-positive cells, theoretically expanding CAR T-cell applications beyond hematologic malignancies. If this approach proves effective, it could open new therapeutic options for cancers that are less responsive to current immunotherapies

Intellectual Property and Competitive Position:

Imugene’s patents, particularly in regions like the U.S. and China, provide a competitive moat if they progress to advanced trial stages. Additionally, they are positioned to license or partner with larger pharmaceutical companies, which could enhance their market access and reduce financial risk associated with late-stage trials

FDA Fast Track and Orphan Drug Designations:

These designations for VAXINIA in bile tract cancer allow for expedited regulatory processes, possibly accelerating Imugene's path to commercialization and improving short-term valuation. However, these designations will only convert to market value if subsequent trials affirm safety and efficacy

Strategic Pathways for Commercialization:

Imugene’s flexibility in pursuing partnerships, out-licensing, or independent commercialization provides multiple options to realize value. This reduces financial risk and allows Imugene to leverage the expertise and distribution networks of established pharmaceutical companies for scaling

In summary, while Imugene's cancer therapies show potential due to novel approaches and differentiated mechanisms, limitations such as early-stage data, small sample sizes, and lengthy regulatory timelines could impact valuation and speed to market. Broader comparisons with FDA-approved treatments and robust Phase 2/3 data will be essential for confirming therapeutic viability and solidifying Imugene’s market position.

Expand

Which is why VAXINIA demonstrating efficacy so early in the clinical trial was excellent and vary rare and show how potent CF33 is. This is why BP will show interest after Ph1 and not near or end of Ph2.

No.	Vol.	Price($)
73	16550519	1.1¢

No.

Vol.

Price($)

16550519

1.1¢

Price($)	Vol.	No.
1.2¢	16163642	28

Price($)

Vol.

No.

1.2¢

16163642

No.	Vol.	Price($)
71	16589469	0.011
79	23253291	0.010
24	7564263	0.009
9	1739999	0.008
5	1780000	0.007

No.

Vol.

Price($)

16589469

0.011

23253291

0.010

7564263

0.009

1739999

0.008

1780000

0.007

Price($)	Vol.	No.
0.012	16125082	27
0.013	13120503	33
0.014	8391947	34
0.015	9008204	32
0.016	7428011	30

Price($)

Vol.

No.

0.012

16125082

0.013

13120503

0.014

8391947

0.015

9008204

0.016

7428011

(20min delay)
Last 1.2¢		Change -0.001(4.17%)		Mkt cap ! $82.13M

Open	High	Low	Value	Volume
1.2¢	1.3¢	1.1¢	$176.2K	14.66M

Ann: Imugene AGM Presentation, page-124

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Juicy copper-zinc target brings GreenTech closer to near-term Whundo production

Australia’s gas crisis is here – and dying coal plants aren’t helping

Wednesday's HotCopper trends: DroneShield in Europe, Humm sale | June 25

Delorean to begin selling carbon offsets under regulation changes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene AGM Presentation, page-124

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Juicy copper-zinc target brings GreenTech closer to near-term Whundo production

Australia’s gas crisis is here – and dying coal plants aren’t helping

Wednesday's HotCopper trends: DroneShield in Europe, Humm sale | June 25

Delorean to begin selling carbon offsets under regulation changes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News